Intrinsic value of Aeglea BioTherapeutics - AGLE

Previous Close

$7.84

  Intrinsic Value

$0.57

stock screener

  Rating & Target

str. sell

-93%

Previous close

$7.84

 
Intrinsic value

$0.57

 
Up/down potential

-93%

 
Rating

str. sell

We calculate the intrinsic value of AGLE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  8
  13
  19
  28
  39
  54
  73
  95
  123
  155
  193
  236
  284
  338
  397
  462
  532
  608
  688
  774
  864
  959
  1,059
  1,164
  1,273
  1,387
  1,505
  1,629
  1,757
  1,891
Variable operating expenses, $m
  48
  75
  112
  162
  228
  314
  422
  554
  712
  900
  1,117
  1,366
  1,646
  1,959
  2,303
  2,679
  3,086
  3,524
  3,991
  4,487
  5,011
  5,563
  6,143
  6,750
  7,383
  8,044
  8,732
  9,448
  10,192
  10,966
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  48
  75
  112
  162
  228
  314
  422
  554
  712
  900
  1,117
  1,366
  1,646
  1,959
  2,303
  2,679
  3,086
  3,524
  3,991
  4,487
  5,011
  5,563
  6,143
  6,750
  7,383
  8,044
  8,732
  9,448
  10,192
  10,966
Operating income, $m
  -40
  -62
  -92
  -134
  -189
  -260
  -349
  -458
  -590
  -745
  -925
  -1,130
  -1,363
  -1,621
  -1,906
  -2,217
  -2,554
  -2,916
  -3,303
  -3,713
  -4,147
  -4,604
  -5,084
  -5,586
  -6,110
  -6,657
  -7,226
  -7,819
  -8,435
  -9,075
EBITDA, $m
  -40
  -61
  -92
  -133
  -188
  -258
  -347
  -455
  -586
  -740
  -919
  -1,124
  -1,354
  -1,611
  -1,895
  -2,204
  -2,539
  -2,899
  -3,283
  -3,691
  -4,122
  -4,576
  -5,053
  -5,552
  -6,073
  -6,617
  -7,183
  -7,772
  -8,384
  -9,020
Interest expense (income), $m
  0
  0
  0
  0
  1
  1
  2
  3
  4
  6
  7
  9
  12
  14
  17
  21
  24
  28
  33
  37
  42
  48
  53
  59
  65
  72
  79
  86
  93
  101
  109
Earnings before tax, $m
  -40
  -62
  -93
  -135
  -190
  -262
  -352
  -462
  -595
  -752
  -934
  -1,142
  -1,377
  -1,638
  -1,927
  -2,242
  -2,583
  -2,949
  -3,340
  -3,756
  -4,195
  -4,658
  -5,143
  -5,651
  -6,182
  -6,736
  -7,312
  -7,912
  -8,536
  -9,184
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -40
  -62
  -93
  -135
  -190
  -262
  -352
  -462
  -595
  -752
  -934
  -1,142
  -1,377
  -1,638
  -1,927
  -2,242
  -2,583
  -2,949
  -3,340
  -3,756
  -4,195
  -4,658
  -5,143
  -5,651
  -6,182
  -6,736
  -7,312
  -7,912
  -8,536
  -9,184

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  19
  29
  44
  64
  90
  124
  166
  218
  280
  354
  440
  538
  648
  771
  907
  1,055
  1,215
  1,387
  1,571
  1,766
  1,973
  2,190
  2,418
  2,657
  2,906
  3,166
  3,437
  3,719
  4,012
  4,317
Adjusted assets (=assets-cash), $m
  19
  29
  44
  64
  90
  124
  166
  218
  280
  354
  440
  538
  648
  771
  907
  1,055
  1,215
  1,387
  1,571
  1,766
  1,973
  2,190
  2,418
  2,657
  2,906
  3,166
  3,437
  3,719
  4,012
  4,317
Revenue / Adjusted assets
  0.421
  0.448
  0.432
  0.438
  0.433
  0.435
  0.440
  0.436
  0.439
  0.438
  0.439
  0.439
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
Average production assets, $m
  1
  2
  3
  4
  6
  8
  11
  14
  18
  22
  28
  34
  41
  49
  58
  67
  77
  88
  100
  112
  125
  139
  154
  169
  185
  201
  218
  236
  255
  274
Working capital, $m
  -2
  -2
  -4
  -5
  -7
  -10
  -14
  -18
  -23
  -29
  -36
  -44
  -53
  -63
  -74
  -86
  -100
  -114
  -129
  -145
  -162
  -179
  -198
  -218
  -238
  -259
  -282
  -305
  -329
  -354
Total debt, $m
  4
  9
  16
  26
  39
  56
  78
  104
  135
  172
  215
  265
  320
  382
  450
  525
  605
  692
  784
  883
  987
  1,096
  1,211
  1,331
  1,456
  1,587
  1,723
  1,865
  2,012
  2,165
Total liabilities, $m
  10
  15
  22
  32
  45
  62
  83
  110
  141
  178
  221
  270
  326
  388
  456
  531
  611
  698
  790
  888
  992
  1,102
  1,216
  1,336
  1,462
  1,593
  1,729
  1,871
  2,018
  2,171
Total equity, $m
  9
  15
  22
  32
  45
  61
  82
  108
  139
  176
  219
  267
  322
  383
  451
  524
  604
  689
  781
  878
  980
  1,088
  1,202
  1,320
  1,444
  1,574
  1,708
  1,848
  1,994
  2,145
Total liabilities and equity, $m
  19
  30
  44
  64
  90
  123
  165
  218
  280
  354
  440
  537
  648
  771
  907
  1,055
  1,215
  1,387
  1,571
  1,766
  1,972
  2,190
  2,418
  2,656
  2,906
  3,167
  3,437
  3,719
  4,012
  4,316
Debt-to-equity ratio
  0.400
  0.620
  0.750
  0.830
  0.880
  0.920
  0.940
  0.960
  0.970
  0.980
  0.990
  0.990
  0.990
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
Adjusted equity ratio
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -40
  -62
  -93
  -135
  -190
  -262
  -352
  -462
  -595
  -752
  -934
  -1,142
  -1,377
  -1,638
  -1,927
  -2,242
  -2,583
  -2,949
  -3,340
  -3,756
  -4,195
  -4,658
  -5,143
  -5,651
  -6,182
  -6,736
  -7,312
  -7,912
  -8,536
  -9,184
Depreciation, amort., depletion, $m
  0
  0
  1
  1
  1
  2
  2
  3
  4
  4
  6
  7
  8
  10
  12
  13
  15
  18
  20
  22
  25
  28
  31
  34
  37
  40
  44
  47
  51
  55
Funds from operations, $m
  -40
  -62
  -92
  -134
  -189
  -260
  -350
  -460
  -592
  -747
  -928
  -1,135
  -1,369
  -1,629
  -1,915
  -2,228
  -2,567
  -2,931
  -3,320
  -3,733
  -4,170
  -4,630
  -5,112
  -5,617
  -6,145
  -6,695
  -7,268
  -7,865
  -8,485
  -9,129
Change in working capital, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
Cash from operations, $m
  -39
  -61
  -91
  -132
  -187
  -258
  -346
  -455
  -586
  -741
  -921
  -1,127
  -1,360
  -1,619
  -1,904
  -2,216
  -2,554
  -2,917
  -3,305
  -3,717
  -4,153
  -4,612
  -5,094
  -5,598
  -6,125
  -6,674
  -7,246
  -7,842
  -8,461
  -9,104
Maintenance CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -6
  -7
  -8
  -10
  -12
  -13
  -15
  -18
  -20
  -22
  -25
  -28
  -31
  -34
  -37
  -40
  -44
  -47
  -51
New CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -5
  -6
  -7
  -8
  -9
  -9
  -10
  -11
  -12
  -12
  -13
  -14
  -14
  -15
  -16
  -17
  -17
  -18
  -19
  -19
Cash from investing activities, $m
  0
  -1
  -1
  -2
  -3
  -3
  -5
  -5
  -7
  -9
  -9
  -12
  -14
  -16
  -19
  -21
  -23
  -26
  -30
  -32
  -35
  -39
  -42
  -46
  -50
  -54
  -57
  -62
  -66
  -70
Free cash flow, $m
  -40
  -62
  -92
  -134
  -190
  -261
  -351
  -461
  -593
  -750
  -931
  -1,139
  -1,373
  -1,635
  -1,923
  -2,237
  -2,578
  -2,944
  -3,334
  -3,750
  -4,189
  -4,651
  -5,136
  -5,644
  -6,174
  -6,727
  -7,304
  -7,903
  -8,526
  -9,174
Issuance/(repayment) of debt, $m
  4
  5
  7
  10
  13
  17
  21
  26
  31
  37
  43
  49
  56
  62
  68
  74
  81
  87
  92
  98
  104
  109
  115
  120
  125
  131
  136
  142
  147
  153
Issuance/(repurchase) of shares, $m
  44
  67
  100
  145
  204
  279
  373
  488
  626
  789
  976
  1,191
  1,432
  1,700
  1,994
  2,315
  2,662
  3,035
  3,432
  3,853
  4,298
  4,766
  5,256
  5,770
  6,306
  6,865
  7,447
  8,052
  8,681
  9,335
Cash from financing (excl. dividends), $m  
  48
  72
  107
  155
  217
  296
  394
  514
  657
  826
  1,019
  1,240
  1,488
  1,762
  2,062
  2,389
  2,743
  3,122
  3,524
  3,951
  4,402
  4,875
  5,371
  5,890
  6,431
  6,996
  7,583
  8,194
  8,828
  9,488
Total cash flow (excl. dividends), $m
  7
  11
  15
  20
  27
  35
  44
  54
  64
  76
  88
  101
  114
  127
  140
  153
  165
  178
  190
  201
  213
  224
  235
  246
  257
  268
  279
  291
  302
  314
Retained Cash Flow (-), $m
  -44
  -67
  -100
  -145
  -204
  -279
  -373
  -488
  -626
  -789
  -976
  -1,191
  -1,432
  -1,700
  -1,994
  -2,315
  -2,662
  -3,035
  -3,432
  -3,853
  -4,298
  -4,766
  -5,256
  -5,770
  -6,306
  -6,865
  -7,447
  -8,052
  -8,681
  -9,335
Prev. year cash balance distribution, $m
  45
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  9
  -56
  -85
  -124
  -177
  -244
  -329
  -435
  -562
  -713
  -888
  -1,090
  -1,318
  -1,573
  -1,854
  -2,163
  -2,497
  -2,857
  -3,242
  -3,651
  -4,085
  -4,541
  -5,021
  -5,524
  -6,049
  -6,597
  -7,167
  -7,761
  -8,379
  -9,021
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  8
  -52
  -74
  -102
  -137
  -177
  -223
  -272
  -323
  -374
  -422
  -465
  -501
  -528
  -544
  -550
  -543
  -526
  -499
  -464
  -422
  -377
  -329
  -281
  -235
  -192
  -154
  -120
  -91
  -68
Current shareholders' claim on cash, %
  30.7
  10.0
  3.3
  1.1
  0.4
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

FINANCIAL RATIOS  of  Aeglea BioTherapeutics (AGLE)

Valuation Ratios
P/E Ratio -4.8
Price to Sales 21.1
Price to Book 1.7
Price to Tangible Book
Price to Cash Flow -5.5
Price to Free Cash Flow -5.5
Growth Rates
Sales Growth Rate -16.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -41.5%
Ret/ On Assets - 3 Yr. Avg. -114.6%
Return On Total Capital -44.4%
Ret/ On T. Cap. - 3 Yr. Avg. -167.4%
Return On Equity -44.4%
Return On Equity - 3 Yr. Avg. -167.4%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -440%
EBITDA Margin - 3 Yr. Avg. -207.8%
Operating Margin -440%
Oper. Margin - 3 Yr. Avg. -207.8%
Pre-Tax Margin -440%
Pre-Tax Margin - 3 Yr. Avg. -207.8%
Net Profit Margin -440%
Net Profit Margin - 3 Yr. Avg. -207.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AGLE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AGLE stock intrinsic value calculation we used $5.205 million for the last fiscal year's total revenue generated by Aeglea BioTherapeutics. The default revenue input number comes from 0001 income statement of Aeglea BioTherapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AGLE stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AGLE is calculated based on our internal credit rating of Aeglea BioTherapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Aeglea BioTherapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AGLE stock the variable cost ratio is equal to 580%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for AGLE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Aeglea BioTherapeutics.

Corporate tax rate of 27% is the nominal tax rate for Aeglea BioTherapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AGLE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AGLE are equal to 14.5%.

Life of production assets of 2.9 years is the average useful life of capital assets used in Aeglea BioTherapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AGLE is equal to -18.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $50.337 million for Aeglea BioTherapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 21.995 million for Aeglea BioTherapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Aeglea BioTherapeutics at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
HZNP Horizon Pharma 21.24 8.86  str.sell
RGNX REGENXBIO 59.01 1.29  str.sell
AGIO Agios Pharmace 63.75 1.63  str.sell
MGNX Macrogenics 16.61 579.51  str.buy
EGRX Eagle Pharmace 49.48 112.77  buy

COMPANY NEWS

▶ Aeglea: 3Q Earnings Snapshot   [Nov-08-18 09:12AM  Associated Press]
▶ Aeglea: 2Q Earnings Snapshot   [Aug-09-18 08:38AM  Associated Press]
▶ 5 Biotech Stocks to Boost Your Portfolios Health This Year   [May-31-18 11:23AM  InvestorPlace]
▶ Aeglea: 1Q Earnings Snapshot   [May-08-18 08:13AM  Associated Press]
▶ Weekly CFO Buys Highlight   [Dec-17-17 03:24PM  GuruFocus.com]
▶ Aeglea reports 3Q loss   [Nov-07-17 05:19PM  Associated Press]
▶ Aeglea reports 2Q loss   [Aug-09-17 09:20PM  Associated Press]
▶ Aeglea Bio shares down 2% after CEO resigns   [Jul-20-17 04:17PM  MarketWatch]
▶ Aeglea reports 1Q loss   [May-09-17 09:33AM  Associated Press]
▶ New Strong Buy Stocks for April 13th   [Apr-13-17 10:52AM  Zacks]
▶ Aeglea reports 4Q loss   [Mar-23-17 04:39PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.